Indication
Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Medicine details

Medicine name:
tildrakizumab (Ilumetri)
SMC ID:
SMC2167
Pharmaceutical company
Almirall Ltd
BNF chapter
Skin
Submission type
Full
Status
Publication due date:
12 August 2019
SMC meeting date:
02 July 2019
Patient group submission deadline:
03 June 2019